Download PDF
Dtsch Med Wochenschr 2013; 138(13): 659-661
DOI: 10.1055/s-0032-1332927
Kommentar | Commentary
Pharmakologie, Genetik
© Georg Thieme Verlag KG Stuttgart · New York

Wo steht die Pharmakogenetik nach 30 Jahren Forschung?

Pharmacogenetics: current state after 30 years of research
M. Eichelbaum
1   Dr. Margarete Fischer-Bosch Institut für Klinische Pharmakologie Stuttgart Universität Tübingen
› Author Affiliations
Further Information

Publication History

13 January 2013

04 February 2013

Publication Date:
19 March 2013 (online)

Also available at
    Permissions and Reprints

Schlüsselwörter

Pharmakogenetik - individualisierte Medizin - personalisierte Therapie

Keywords

pharmacogenetics - individualized medicine - personalized therapy
 

  • Literatur

  • 1 Brauch H, Schroth W, Goetz MP et al. Tamoxifen use in postmenopausal breast cancer: CYP2D6 matters. J Clin Oncol 2012; 31: 176-180
    PubMedGoogle Scholar
  • 2 Daly AK, Day CP. Genetic association studies in drug-induced liver injury. Drug Metab Rev 2012; 44: 116-126
    CrossrefPubMedGoogle Scholar
  • 3 Eichelbaum M, Ingelman-Sundberg M, Evans WE. Pharmacogenomics and individualized drug therapy. Annu Rev Med 2006; 57: 119-137
    CrossrefPubMedGoogle Scholar
  • 4 Ge D, Fellay J, Thompson AJ et al. Genetic variation in IL28B predicts hepatitis Ctreatment-induced viral clearance. Nature 2009; 461: 399-401
    CrossrefPubMedGoogle Scholar
  • 5 Klein TE, Altmann RB et al. Estimation of the Warfarin dose with clinical and pharmacogenetic data. The International Warfarin Pharmacogenetics Consortium. N Engl J Med 2009; 360: 753-764
    CrossrefPubMedGoogle Scholar
  • 6 Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA 1998; 279: 1200-1205
    Google Scholar
  • 7 McCormack M, Alfirevic A, Bourgeois S et al. HLA-A*3101 and carbamazepine-induced hypersensitivity reactions in Europeans. N Engl J Med 2011; 364: 1134-1143
    CrossrefPubMedGoogle Scholar
  • 8 Rae JM, Drury S, Hayes DF et al. ATAC trialists. CYP2D6 and UGT2B7 genotype and risk of recurrence in tamoxifen-treated breast cancer patients. J Natl Cancer Inst 2012; 104: 452-460
    CrossrefPubMedGoogle Scholar
  • 9 Regan MM, Leyland-Jones B, Bouzyk M et al. CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the breast international group 1-98 trial. J Natl Cancer Inst 2012; 104: 441-451
    CrossrefPubMedGoogle Scholar
  • 10 Shuldiner AR, O'Connell JR, Bliden KP et al. Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. JAMA 2009; 302: 849-857
    CrossrefPubMedGoogle Scholar